ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gout and Crystalline Arthritis

Urate-Lowering Therapy in the Treatment of Patients with Chronic Kidney Disease

Summarized from The New England Journal of Medicine  |  December 2, 2024

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

Top Research in Gout from ACR Convergence 2024 at a Glance

Lisa Stamp, MBChB, PhD  |  November 23, 2024

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.

Better Education on Gout

Mary Beth Nierengarten  |  November 22, 2024

Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.

Lubricin/CD44/PP2A Pathway Offers New Therapeutic Targets for Patients with Gout

Ruth Jessen Hickman, MD  |  November 22, 2024

Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.

Progress in Gout Education & Remission

Glen Rodman  |  September 27, 2024

An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.

Novel Mechanisms of Gout Explored

Glen Rodman  |  September 27, 2024

In a session at ACR Convergence 2024, expert panelists with go into depth concerning molecular mechanisms that contribute to gout pathogenesis.

Your Gout Guide for ACR Convergence 2024: Dr. Lisa Stamp

Glen Rodman  |  September 25, 2024

Lisa Stamp, MBChB, PhD, is here to help the busy clinician by curating a collection of the most significant and notable abstracts in gout research to be presented at ACR Convergence 2024.

3 AC&R Study Summaries: Frailty & Prefrailty in RA, Premature Mortality in Gout & Using Recruitment & Multidisciplinary Care Incentives to Improve Access

Arthritis Care & Research  |  May 5, 2024

Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…

Gout & Its Comorbidities

Larry Beresford  |  January 22, 2024

At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.

Old Disease, New Tricks: A Novel Approach to Understanding Gout

Jason Liebowitz, MD, FACR  |  December 7, 2023

SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 22
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences